Obesity intervention needed before pregnancy

December 06, 2018

New research from the University of Adelaide's Robinson Research Institute supports the need for dietary and lifestyle interventions before overweight and obese women become pregnant.

The researchers have reported the results of a large study of birth outcomes in more than 500 overweight or obese women from three public maternity units in Adelaide, Australia in The Lancet Diabetes & Endocrinology.

The GRoW (Metformin for Gestational Restriction of Weight in pregnant women) trial was designed to reduce risks for pregnant women who are overweight or obese.

The researchers investigated the potential of the use of common diabetes medication metformin during pregnancy to reduce pregnancy weight gain and improve pregnancy outcomes. Research trials conducted elsewhere previously had conflicting findings.

"In high-income countries, roughly 50% of women are already overweight or obese when they become pregnant," says project leader Professor Jodie Dodd, Professor of Obstetrics and Gynaecology in the University of Adelaide's Robinson Research Institute and maternal fetal medicine specialist at the Women's and Children's Hospital.

"This places both the mother and her infant at risk of a range of pregnancy and birth outcomes and can also lead to high infant birthweight, which in turn can lead to childhood obesity."

The study enrolled women who were pregnant and overweight or obese; half of the women were given a medication called metformin, usually used for the treatment of type 2 diabetes. All women were given advice on healthy diet and lifestyle.

The researchers found that taking metformin reduced weekly pregnancy weight gain and women were more likely to gain below current recommendations, but this did not reduce the risk of having a baby with birthweight over 4kg. Nor did it reduce the risk of high blood pressure, gestational diabetes or birth by caesarean.

While Metformin has been used in previous studies of obesity in pregnancy, this study is the first to include women who were overweight, as well as obese, and the first to combine the medication with dietary and lifestyle advice.

"We've now seen a lot of studies showing that dietary and lifestyle advice for pregnant women who are overweight or obese to improve the health of women and their children has very limited benefit," says Professor Dodd.

"This study supports that outcome. We need to consider dietary and lifestyle interventions prior to women becoming pregnant if we are going to break the cycle of intergenerational obesity."
-end-
Media Contact:

Professor Jodie Dodd, Robinson Research Institute, University of Adelaide and Women's and Children's Hospital. Phone: +61 8 8161 7615, Mobile: +61 (0)451 631 000, jodie.dodd@adelaide.edu.au.

Robyn Mills, Media Officer. Phone: +61 8 8313 6341, Mobile: +61 (0)410 689 084, robyn.mills@adelaide.edu.au

University of Adelaide

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.